A Flexible Algorithm for a Variable Disease: Treating Pheochromocytoma and Paraganglioma

Published on September 14, 2026

Endocrine News speaks with Camilo Jimenez, MD, about his JCEM paper “Approach to the patient with metastatic pheochromocytoma and paraganglioma: advances in systemic therapy” that focuses on treating a patient with pheochromocytomas and paragangliomas, its complexity, and his team’s algorithm that created a novel approach to guiding treatment decisions. Pheochromocytomas and paragangliomas (PPGLs) are all […]

The post A Flexible Algorithm for a Variable Disease: Treating Pheochromocytoma and Paraganglioma appeared first on Endocrine News.

Continue reading on website
Other news

Pharma Friday – Sept. 11, 2026

September 11, 2026
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases On Sept. 8, Moonwalk Biosciences, a biotechnology company developing adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic

NIH launches $21 million initiative to improve understanding of sex-specific hormonal biology 

September 14, 2026
Program will use new approaches in computational modeling for deeper investigations into how sex influences treatment response. The National Institutes of Health (NIH) is awarding $21 million to launch a research program aimed at spurring the development of computer-based methods that model and simulate the self-regulating processes of human hormones, known as hormone homeostasis. Hormone […]The p